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Background: Transcatheter aortic valve implantation (TAVI) is an alternative treatment for high-risk patients with aortic valve disease. Herein, we 
investigated the efficacy and outcome of TAVI in patients with low-flow, low-gradient aortic stenosis (LG-AS) based on data from the prospective 
multicentre German Transcatheter Aortic Valve Interventions-Registry.
Methods and Results: Between January 2009 and June 2010, a total of 1302 patients undergoing TAVI were included in the registry. LG-AS 
was present in 149 (11.4%) patients with a mean age of 80.2±6.3 years (57.0% males; EF 37.8±14.4; mean pressure gradient 31.3±13.3). In this 
subgroup, the EuroScore was significantly higher (26.8±16.6 vs. 20.0±13.3; p<0.0001) compared to atients with high-gradient aortic stenosis (HG-
AS). In 87.9% of LG-AS-patients, the procedure was performed transfemorally. Procedural success was achieved in 95.3% with a mean postoperative 
gradient of 5.6±5.3mmHg. Compared to HG-AS patients, there was a higher rate of urgent TAVI-procedures in the LG-AS subgroup (24.8% vs. 
14.5%; p<0.01). The rate of TAVI-associated complications was comparable in both groups (permanent pacemaker: 33.8% vs. 35.4%; p=0.77; 
cerebrovascular events: 3.4% vs. 3.1%, p=0.83). However, postoperative low output occurred more frequently in patients with LG-AS (LG-AS: 14.9% 
vs. HG-AS: 5.7%, p<0.00001) and mortality at 30 days and 1 year were significantly higher in this subgroup (LG-AS 12.8% and 36.9% vs. HG-AS 
7.4% and 18.1%; p<0.001 and p<0.0001). In both groups, there was a significant postoperative improvement in NYHA functional class and self-
assessed quality of life, demonstrating the substantial benefit of TAVI also in patients with LG-AS. 
Conclusion: In high-risk patients with LG-AS, TAVI is associated with a significantly higher mortality at 30 days and at 1 year. However, long-term 
survivors benefit from TAVI with functional improvement and a significantly increased quality-of-life. Therefore, in view of the poor prognosis with 
medical treatment TAVI should be considered as treatment option in high-risk patients with LG-AS. 
